Investor Presentaiton

34 USA Trial: NCT04177498 Study Population: RDEB patients with advanced SCC who have failed prior standard of care. Primary Objectives: To estimate the anti-tumor activity of oral or IV rigosertib by determining the overall response rate, defined as the proportion of patients who achieve either a complete response or a partial response by RECIST v1.1 criteria To evaluate the safety and tolerability of oral rigosertib administered daily three weeks on, one week off for 12 cycles or IV rigosertib administered as continuous 72h IV infusions once every two weeks for 8 cycles and then once every 4 weeks thereafter 0 ONCONOVA THERAPEUTICS

View entire presentation